Ultimo aggiornamento :
19/11/2024
Ansiolitico   Midazolam hydrochloride  
Iniezione
Capsula Soluzione orale
Stabilità in soluzione Stabilità in miscela Fattori che influenzano la stabilità Compatibilità metodo di iniezione Bibliografia pdf
   Struttura chimica  

Nome commerciale   Nome commerciale     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Benzosed Ecuador, India, Venezuela
Buccolam Belgio, Germania
Crismidor Colombia
Dalam Argentina
Dormicum Africa del Sud, Arabia Saudita, Argentina, Austria, Belgio, Colombia, Croazia, Danimarca, Egitto, Emirati Arabi Uniti, Finlandia, Germania, Grecia, Irlanda, Messico, Paesi Bassi, Polonia, Portogallo, Romania, russo, Slovenia, Spagna, Svezia, Svizzera, Turchia, Ungheria
Dormipron Colombia
Dormire Brasile, Chile
Dormomid Brasile, Chile
Gobbizolam Argentina
Hipnazolam Brasile
Hypnovel Australia, Francia, Gran Bretagna, Marocco, nuova Zelanda
Induson Brasile, Colombia
Lamcord Messico
Midanium Polonia
Midasedan Colombia
Midaselect Germania
Midozor Messico
Relacum Brasile, Colombia, Ecuador, Messico
Sedoz Colombia
Somnocal Messico
Sopodorm Polonia
Zolamid Portogallo, Turchia
Zolmid Chile
Bibliografia   Iniezione   Bibliografia : Midazolam hydrochloride  
tipo pubblicazione
5 Rivista Stiles ML, Allen LV Jr, Prince SJ.
Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes.
Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
41 Rivista Pramar YV, Loucas VA, El-Rachidi A.
Stability of midazolam hydrochloride in syringes and IV fluids.
Am J Health-Syst Pharm 1997 ; 54: 913-915.
59 Rivista Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73 Rivista Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
86 Rivista Johnson CE, Bhatt-Mehta V, Mancari SC, McKown JA.
Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration.
Am J Hosp Pharm 1994 ; 51: 2812-2815.
93 Rivista Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
150 Rivista Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
176 Rivista Mantong ML, Marquardt ED.
Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
185 Rivista McMullin ST, Burns Schaiff RA, Dietzen DJ.
Stability of midazolam hydrochloride in polyvinyl chloride bags under fluorescent light.
Am J Health-Syst Pharm 1995 ; 52: 2018-2020.
186 Rivista Swart EL, Mooren RAG, Van Loenen AC.
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
215 Rivista Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426.
225 Rivista Bhatt-Mehta V, Johnson CE, Leininger N, Agarwal M.
Stability of fentanyl citrate and midazolam hydrochloride during simulated intravenous coadministration.
Am J Health-Syst Pharm 1995 ; 52: 511-513.
231 Rivista Hagan RL, Jacobs III LF, Pimsler M, Merritt GJ.
Stability of midazolam hydrochloride in 5% dextrose injection or 0.9% sodium chloride injection over 30 days.
Am J Hosp Pharm 1993 ; 50: 2379-2381.
232 Rivista Bhatt-Mehta V, Rosen DA, King RS, Marsym CJ.
Stability of midazolam hydrochloride in parenteral nutrient solutions.
Am J Hosp Pharm 1993 ; 50: 285-288.
285 Rivista Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255.
295 Rivista Yamashita SK, Walker SE, Choudhury T, Iazzetta J.
Compatibility of selected critical care drugs during Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299 Rivista Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Rivista Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Rivista Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314 Rivista Chiu MF, Schwartz ML.
Visual compatibility of injectable drugs used in the intensive care unit.
Am J Health-Syst Pharm 1997 ; 54: 64-65.
319 Rivista Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999.
345 Rivista Walker SE, Meinders A, Tailor H.
Stability and compatibility of reconstituted sterile hydromorphone with midazolam.
Can J Hosp Pharm 1996 ; 49: 290-298.
350 Rivista Martens HJ, De Goede PN, Van Loenen AC.
Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers.
Am J Hosp Pharm 1990 ; 47: 369-373.
398 Rivista Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
399 Rivista Bleasel MD, Peterson GM, Jestrimski KW.
Stability of midazolam in sodium chloride infusion packs.
Aust J Hosp Pharm 1993 ; 23: 260-262.
401 Rivista Peterson GM, Khoo BHC, Galloway JG, Paterson J.
A preliminary study of the stability of midazolam in polypropylene syringes.
Aust J Hosp Pharm 1991 ; 21: 115-118.
402 Rivista Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
404 Rivista Forman JK, Souney PF.
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
Am J Hosp Pharm 1987 ; 44: 2298-2299.
496 Rivista Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
660 Rivista Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
813 Rivista Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68.
815 Rivista Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
865 Rivista Bhatt-Mehta V, Hirata S.
Physical compatibility and chemical stability of atracurium besylate and midazolam hydrochloride during intravenous coinfusion.
Int J Pharm Compound 1998 ; 2: 79-81.
896 Rivista Bianchi C, Airaudo CB, Gayte-Sorbier A.
Sorption studies of dipotassium clorazepate salt (Tranxene®) and midazolam hydrochloride (Hypnovel®) in polyvinyl chloride and glass infusion containers.
J Clin Pharm Ther 1992 ; 17: 223-227.
921 Rivista Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
929 Rivista Wilson KM, Schneider JJ, Ravenscroft PJ.
Stability of midazolam and fentanyl in infusion solutions.
J Pain Symptom Manage 1998 ; 16: 52-58.
939 Rivista Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
1067 Rivista Zeidler C, Dettmering D, Schrammel W, Spieteller M.
Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers.
EJHP 1999 ; 5: 106-110.
1288 Rivista Allwood MC, Brown PW, Lee M.
Stability of injections containing diamorphine and midazolam in plastic syringes.
Int J Pharm Pract 1994 ; 3: 57-59.
1405 Rivista Peterson GM, Miller KA, Galloway JG, Dunne PF.
Compatibility and stability of fentanyl admixtures in polypropylene syringes.
J Clin Pharm Ther 1998 ; 23: 67-72.
1415 Rivista Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1419 Rivista Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM.
Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride.
Int J Pharm Compound 1999 ; 3: 235-238.
1492 Rivista LeBelle MJ, Savard C, Gagnon A.
Compatibility of morphine and midazolam or haloperidol in parenteral admixtures.
Can J Hosp Pharm 1995 ; 48: 155-160.
1506 Rivista Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.
EJHP 2015 ;22:107-112.
1508 Rivista Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1512 Laboratorio Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015
1603 Rivista Bergquist PA, Manas D, Hunke WA, Reed RA.
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611 Rivista Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 Rivista Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1637 Rivista Wong AH, Law S, Walker SE, Bowles SK.
Concentration-dependant compatibility and stability of dexamethasone and midazolam.
Can J Hosp Pharm 2000 ; 53: 24-31.
1713 Rivista Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Rivista Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1759 Rivista Servais H, Tulkens PM.
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803 Rivista Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1866 Rivista Vermeire A, Remon JP.
Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone.
Int J Pharm 1998 ; 174: 157-177.
1887 Rivista Andersin R, Tammilehto S.
Photochemical decomposition of midazolam. IV . Study of pH dependant stability by high-performance liquid chromatography.
Int J Pharm 1995 ; 123: 229-235.
1888 Rivista Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A.
Compatibility study of midazolam.
Ziekenhuisfarmacie 1986 ; 2: 45-48.
1901 Rivista Good PD, Schneider JJ, Ravenscroft PJ.
The compatibility and stability of midazolam and dexamethasone in infusion solutions.
J Pain Symptom Manage 2004 ; 27, 5: 471-475.
1902 Rivista Walker SE, Wyllie A, Law S.
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.
Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925 Rivista Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1944 Rivista Hartman CA, Faria CE, Mago K.
Visual compatibility of bivalirudin with selected drugs.
Am J Health-Syst Pharm 2004 ; 61: 1774.
1964 Rivista Hartman CA, Baroletti SA, Churchill WW et al.
Visual compatibility of argatroban with selected drugs.
Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1971 Rivista Azuara ML, Sanchez Y, Reyes R, Barcia E.
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Support Care Cancer 2001
1974 Rivista Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1975 Rivista Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 235-237.
1982 Rivista Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018 Rivista Veggeland T.
Visual compatibility of clonidine with selected drugs.
Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2083 Rivista La Forgia SP, Sharley NA, Burgess NG, Doecke CJ.
Stability and compatibility of morphine, midazolam and bupivacaine combinaisons for iontravenous infusion.
J Pharm Pract and Res 2002 ; 32: 65-68.
2090 Rivista Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2108 Rivista Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2109 Rivista Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75.
2125 Rivista Gardiner PR.
Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration.
Hospital Pharmacist 2003 ; 10: 354-361.
2139 Rivista Serrurier C, Chenot ED, Vigneron J, May I, Demor? B.
Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities.
EJHP Science 2006 ; 12,5: 96-99.
2141 Rivista Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2166 Rivista Nassr S, Dubuc MC, Lavoie P, Brazier JL.
HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine.
J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929.
2231 Rivista de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247 Rivista Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Rivista Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Rivista Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2376 Rivista de Diego M, Godoy G, Mennikent S.
Chemical stability of midazolam injection by high performance liquid chromatography.
J Sep Sci 2007 ; 30, 12: 1233-1238.
2900 Rivista Hines S, Pleasance S.
Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration.
EJHP 2009 ; 15, 5: 32-38.
3012 Rivista Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3134 Rivista Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM.
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.
Enferm Intensiva 2010 ; 21: 96-103.
3152 Rivista Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3176 poster Humbert Delaloye V, Berger M, Voirol P, Pannatier A.
Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté.
16èmes JFSPH, Sion, 18-19 novembre 2010
3212 Rivista Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M.
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos.
Enferm Intensiva 2011 ;22:78-82.
3216 Rivista Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3222 Rivista Karlage K, Earhart Z, Green-Boesen K, . Myrdal PB
Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags
Am J Health-Syst Pharm 2011 ;68:1537-1540.
3249 Rivista Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3294 Rivista Humbert-Delaloye V, Berger M, Voirol P, Pannatier A.
In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs
EJHP 2012 ; 19: 57-64.
3372 Rivista Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3379 Rivista Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3385 Rivista Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408 Rivista Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3463 Rivista Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R.
Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad.
Nursing 2011 ; 29 :62-6
3464 Rivista Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau.
Compatibilidad física de la amiodarona en perfusión continua
Enferm Clin 2011 21:25-29.
3465 Rivista E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?.
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.
Enferm Intensiva 2010 ;21:96-103.
3466 Rivista B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau.
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos
Enferm Intensiva 2011 ;22:78-82.
3521 Laboratorio Tramadol® - Summary of Product Characteristics.
Beacon Pharmaceuticals 2012
3571 Rivista Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3601 Laboratorio Cisatracurium Actavis - Résumé des Caractéristiques du Produit
Actavis 2012
3617 Laboratorio Hyaluronidase (Hyalase®) - Summary of Product Characteristics
Wockhardt 2011
3705 Rivista Knudsen L, Eisend S, Haake N, Kunze T.
Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine.
EJHP 2014 ;21:161-166
3728 Rivista Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766 Rivista Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Rivista Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3781 Rivista Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A
Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide.
EJHP 2015 ;22:1 56-58
3823 Rivista Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152.
3824 Rivista Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3932 Laboratorio Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
Serb Laboratoire 2015
3934 Laboratorio Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016
3948 Rivista Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
3964 Rivista Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3976 Rivista Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3989 Rivista Feutry F, Genay S, Velghe C, Barthélémy C, Décaudin B, Odou, P.
Stability of midazolam and noradrenaline stored in cyclic olefin copolymer AT-Closed Vials® and polypropylene syringes during 365 days.
Pharmaceutical Technology in Hospital Pharmacy 2017 ; 2,1: 35
4011 Rivista Gersonde F, Eisend S, Haake N, Kunze T.
Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit.
EJHP 2016 2016;0:1-11
4055 Rivista Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119 poster Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P.
Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®)
Hôpitaux Universitaire de Genève 2004
4145 Rivista Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4201 Rivista Gilliot S, Masse M, Feutry F, Barthélémy C, Décaudin B, Genay S, Odou P.
Long-term stability of ready-to-use 1-mg/mL midazolam solution.
Am J Health-Syst Pharm 2020 ; 77, 9: 681-689.
4303 Rivista Anderson C, MacKay M.
Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes.
Pharmacy 2015 3, 379-385.
4319 Rivista Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4332 poster Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI)
Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI).
JFSPH 2019 2019
4366 Rivista Estan-Cerezo G, Rodriguez-Lucena F.J, Matoses Chirivella C, Jiminez-Pulido I, Garcia-Monsalve A, Navarro-Ruiz A.
Midazolam and haloperidol for palliative sedation: physicochemical stability and compatibility of parenteral admixtures.
Braz J Pharm Sci 2019 ;55:e17351
4389 Rivista Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4404 poster Müller U, Haller F, Wiedemeier P, Steuer C.
Compatibility studies of seven commonly used drugs for parenteral administration in palliative care.
JFSPH 2019 2019
4419 Rivista Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4428 Rivista Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433 Rivista Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4434 Rivista Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4435 Rivista Hanifah S, Nugroho B.H, Chabib L.
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4470 Rivista Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P.
Continuous versus intermittent infusion of temocillin in intensive care unit patient.
Critical care 2005 ; 9(Suppl 1) P37
4491 Rivista De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2020
4528 Rivista Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4538 Rivista Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K.
Compatibility of pentoxifylline and parenteral medications.
Archives of Disease in Childhood 2020 ; 105: 395-397.
4543 Rivista Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4545 Rivista Kondo M, Nagano M, Yoshida M, Yoshida N, Tagui N, Yoshida M, Sugaya K, Takase H.
Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment.
Journal of Nippon Medical school 2021
4550 Rivista Semark, A.J, Venkatesh, K, McWhinney B.C, Pretorius, C, Roberts, J.A, Cohen J, Venkatesh B.
The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration.
Crit Care Resusc 2013 ;15, 1: 63–66.
4603 Rivista Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4605 Rivista Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P.
Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility.
Ann Allergy 2012 ; 2:28.
4650 Laboratorio Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4651 Rivista De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2021 ;180,1169–1176.
4654 poster Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021
4698 Rivista Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022
4723 Rivista Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H
Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration.
Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4742 Rivista Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.
4801 Rivista Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:
4802 Laboratorio Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit
Aguettant Laboratory 2021
4837 Rivista De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087.

  Mentions Légales